<DOC>
	<DOCNO>NCT00346749</DOCNO>
	<brief_summary>This study evaluate effect two medicine COPD ( Chronic Obstructive Pulmonary Disease ) . The study last 12 week . At end 12 week treatment , subject stop study medicine 2 week . The study involve 6 visit clinic . Subjects elect undergo bronchoalveolar lavage ( BAL ) procedures 8 study visit . Subjects give sputum , blood , case BAL sample . Subjects breathe test complete diary card study . All study medicine examination give cost study subject . Both medicine use study approve US FDA .</brief_summary>
	<brief_title>ADVAIR DISKUS速 ( Fluticasone Propionate/Salmeterol ) Inhaler Versus SEREVENT DISKUS速 ( Salmeterol ) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease . ADVAIR DISKUS速 SEREVENT DISKUS速 Inhalers Are Trademarks GSK Group Companies .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Diagnosis COPD . Prebronchodilator FEV1 less equal 70.0 % great equal 0.70L ExSmokers least 10 packyear history . Current secondary diagnosis asthma current diagnosis atopy . Other respiratory disorder COPD . Other inflammatory disease . Abnormal clinically significant chest xray ECG . Lung resection surgery within past 1 year . History cancer remission within past 2 year . Serious , uncontrolled disease . Pregnancy plan become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>FEV1</keyword>
	<keyword>Sputum</keyword>
</DOC>